Immunoglobulin for low antibodies after CAR T-cell therapy
Part of Immune system & allergy clinical trials.
This trial tests whether giving immunoglobulin (a treatment that boosts your antibodies) can help people who developed very low antibody levels after CAR T-cell therapy for cancer. It may help prevent infections and improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You received CD19-targeted CAR T-cell therapy in the last 6 months
- Your blood tests show very low IgG antibody levels (below 4 g/L)
- You are willing to receive plasma-derived medicines
- You do not have conditions that cause protein loss (like kidney or gut problems)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a medicine called IgPro20 can help prevent infections in people with multiple myeloma who have low antibody levels and are being treated with a bispecific antibody. If you have relapsed or refractory myeloma and have recently started a bispecific antibody, this study might help protect you from getting serious infections.
This Phase 2 study tests whether IVIG (a blood product that helps fight infections) can lower infection risk after you receive CD19 CAR-T therapy. It’s meant to help protect you during the vulnerable period after CAR-T treatment.
This study compares two ways to prevent infections in people who have had CAR-T cell therapy for B-cell leukemia or lymphoma. One group receives regular antibody infusions, and the other takes daily antibiotics. The goal is to see which approach works better and is safer.
This study tests a new immunoglobulin (antibody) treatment called IgPro20 in adults whose immune systems became weakened after receiving CAR-T cell or TCE therapies for blood cancers. The goal is to help strengthen your immune system and reduce infection risk.
This trial tests a new immunoglobulin treatment (V-Immune) for people with primary IgG deficiency who are already on IVIG therapy. It aims to see if this new therapy can effectively replace their current treatment.
This trial tests whether giving immunoglobulin to adults with low antibody levels can prevent infections. It aims to compare immunoglobulin with antibiotic therapy or no added treatment for people with blood conditions.
Hear when a new Hypogammaglobulinemia, Acquired trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.